SCHEMBL22366366

SCHEMBL22366366

CC(C)(C)OC(=O)c1ccc(Cl)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
ABL1 P00519 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
NR1H4 Q96RI1 1/20 0.39
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477523 0.87 CNR1 (0.42) ABL1CNR1CNR2NR1H4GABRA1
SCHEMBL3842336 0.83 L3MBTL1 (0.41) FLT1FLT4KDRGABRA1GABRG2
SCHEMBL3843873 0.83 NR1H4 (0.54) CNR1CNR2NR1H4TSHRCASP1
SCHEMBL7594883 0.81 CA12 (0.46) GABRA1GABRG2GABRB3CASP1MAPT
SCHEMBL7564043 0.81 CISD2 (0.37) CNR1CNR2TSHRSMN1; SMN2MAPT
SCHEMBL27589526 0.81 FLT1 (0.44) FLT1FLT4KDRABL1CNR1
SCHEMBL610371 0.81 ABL1 (0.64) FLT1FLT4KDRABL1CASP1
SCHEMBL17644983 0.80 FLT1 (0.48) FLT1FLT4KDRABL1SMN1; SMN2
SCHEMBL17480688 0.80 ABL1 (0.42) ABL1CNR1CNR2NR1H4GABRA1
SCHEMBL14329237 0.80 GABRG2 (0.43) GABRA1GABRG2GABRB3GABRA5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2023-12-05 US disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
CN-111511750-B Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2023-06-13 CN disclosed
EP-3700911-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier SAS (FR) 2020-09-02 EP disclosed
CN-111511750-A Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2020-08-07 CN disclosed
CN-110256245-A A kind of synthetic method of the chloro- 2- bromobenzoic acid tert-butyl ester of 4- 常州合全药业有限公司 2019-09-20 CN disclosed
CN-110256245-A A kind of synthetic method of the chloro- 2- bromobenzoic acid tert-butyl ester of 4- 常州合全药业有限公司 2019-09-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same C1R, F12, RDX FLT1 1866/4885FLT4 2875/4885KDR 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.